1. Annual report 2024
  2. Research
  3. MARCEVAP

MARCEVAP

Disease, Cardiovascular Risk and Lifestyle in Primary Care Research Group

It is a multidisciplinary research group in primary care, with a predominantly healthcare profile with the support of professionals with a more methodological profile. The aim of the group is to seek evidence-based responses to the clinical challenges of prevention and care for people with kidney disease and other chronic pathologies, the associated cardiovascular risk, with special attention to the approach to lifestyles.

The renal disease line addresses the prevalence, incidence, risk factors, management and associated cardiovascular risk of both mild-moderate chronic kidney disease and advanced disease to prevent progression to end-stage renal disease and its complications. Lifestyle research, in an approach based on the prevention and reduction of cardiovascular risk, includes the care of smokers, the promotion of physical activity, diet and the effects of lifestyle on health. 

Group projects

  • Stay at ISGlobal research centre, MARCEVAP GROUP. (EST-23/3). Jordi Gol i Gurina Primary Care Research Institute (IDIAPJGol). 2024-2025. IP: Laura Illamola Martin.
  • Ealuation of the use of mobile health interventions (mSalut) in lifestyles in Primary Care (PC). (INTENS-23/14). ICS Catalan Institute of Health. 2024-2026. PI: Francesc Alòs Colomer.
  • Disease, cardiovascular risk and lifestyles in primary care (MARCEVAP). (SENIOR-23/5). ICS - Catalan Institute of Health. 2024-2026. IP: Yolanda Rando Matos.
  • Chronic kidney disease (CKD) in Catalonia. Progression, regression and type of patients who receive or not renal replacement therapy in end-stage renal failure (ESRD). ICS - Catalan Institute of Health. 2023IP: Daniel Bundo Luque. - Baix Llobregat Health Awards 2022. Official College of Physicians of Barcelona. IP: Bethlehem Salvador Gonzalez.
  • USR Metro Sud. IP: Bethlehem Salvador Gonzalez. - Mobile app for nystagmographies incorporated into a diagnostic algorithm for benign paroxysmal peripheral vertigo. NYSTAVERT. Primary Care Foundation (FAP) - CAMFIC; Migranodearena Foundation. PI: José Luis Ballvé Moreno.
  • Pilot test of an exercise program and dietary advice to improve quality of life and decrease sarcopenia in postmenopausal women with osteoporosis. Spanish Society of General and Family Physicians (SEMG). 2024-2027. IP: Laura Illamola Martin.
  • Community intervention to deprescribe benzodiazepines in patients with insomnia and anxiety. Generalitat Catalunya. 2024-2027. IP: Laura Illamola Martin.
  • Joint Action on CARdiovascular diseases and DIabetes (JACARDI). (101126953). European Commission. 2023-2027. IP: Bethlehem Salvador Gonzalez.
  • Evaluation of muscle mass with ultrasound for the early approach to sarcopenia in inactive older adults in primary care. 2023-2026. IP: Laura Illamola Martin.
  • Evaluation of muscle mass with ultrasound for the early approach to sarcopenia in active older adults in primary care. 2023-2026. IP: Laura Illamola Martin.
  • Pilot trial of an exercise program to improve quality of life and decrease sarcopenia in postmenopausal women with osteoporosis. Spanish Society of General and Family Physicians (SEMG). 2023-2026. IP: Laura Illamola Martin.
  • Real World Burden of Chronic Kidney Disease A Population-Based Study In Catalonia, Northeast Spain. Boehringer Ingelheim España, S.A. 2023-2026. IP: Bethlehem Salvador Gonzalez.
  • Use of wearable devices and mobile health applications (mSalut) to change lifestyles in Primary Care. (BR028). ICS - Catalan Institute of Health. 2022-2025. PI: Francesc Alòs Colomer.
  • Design and evaluation of a multidisciplinary comprehensive care program in Advanced Chronic Kidney Disease (MaReCA). (SLT021/21/000031). Generalitat Catalunya. 2022-2025. IP: Iris Lumillo Gutiérrez.
  • Sarconut: pilot test to prevent ATDOM sarcopenia. Mutuam Conviure Foundation. 2021-2025. IP: Laura Illamola Martin.
  • Avaluació de l'impacte de l'obertura de l'oci nocturn - Reobrim Sitges. ICS - Institut Català de la Salut. 2021-2024. IP: Betlem Salvador Gonzalez.
  • Effectiveness of a training intervention to improve the approach to patients with vertigo in primary care. VERTAP clinical trial. (PI19/00736). Carlos III Health Institute. 2019-2024. PI: José Luis Ballvé Moreno.
  • Prognosis of CKD: a population-based epidemiological study. Bayer AG. 2019IP: Betlem Salvador González.
  • Should chronic kidney disease be treated as secondary prevention? Risk of coronary events in chronic kidney disease, diabetes mellitus, and cardiovascular disease in individuals aged 60 to 79 years. Col.legi Oficial de Metges de Barcelona. 2019-2024. PI: Silvia Cobo Guerrero.

Group publications

  • Cruz A, Cuxart Graell A, Goncalves AQ, Vazquez Villegas J, Vallejo Godoy S, Salas Coronas J et al. Delivering an innovative multi-infection and female genital mutilation screening to high-risk migrant populations (ISMiHealth): study protocol of a cluster randomised controlled trial with embedded process evaluation. BMJ Open. 2024; 14(11):PMID:39496367.
  • Martin LI, Granados AG, Melenchon AS, Cristobal JJR, Hernandez MB. Prevalence of physical inactivity and risk of sarcopenia in primary care. Cross-sectional study. Aten Primaria. 2024; 56(11):102993-102993. PMID:38875834.
  • Bonet Monné S, Urgell CV, Sáez MJP, Puertolás OC, Baena Díez JM, Pascual J et al. NSAIDs, analgesics, antiplatelet drugs, and decline in renal function: a retrospective case-control study with SIDIAP database. BMC Pharmacol Toxicol. 2024; 25(1):58-58. PMID:39198874.
  • Alòs F, Mínguez DA, Cárdenas Ramos M, Cancio Trujillo JM, Zaldúa YC, Puig Ribera A. Mobile health in primary care. New challenges in the development of solutions to promote physical activity and well-being. Aten Primaria. 2024; 56(8):102900-102900. PMID:38479201.
  • Pérez Vega KA, Sanllorente A, Zomeño MD, Quindós A, Muñoz Martínez J, Malcampo M et al. Sourdough Bread with Different Fermentation Times: A Randomized Clinical Trial in Subjects with Metabolic Syndrome. Nutrients. 2024; 16(15):PMID:39125261.
  • Illamola L. Evaluación de un programa de ejercicio y consejos de alimentación para prevenir la sarcopenia en pacientes domiciliarios en atención primaria. Rev Esp Nutr Comunitaria. 30
  • Garcia Gil M, Alves Cabratosa L, Cunillera O, Blanch J, Martí Lluch R, Ponjoan A et al. Effectiveness of the low-density lipoprotein cholesterol goals in secondary cardiovascular prevention. Eur. J. Clin. Invest. 2024; 54(9):PMID:38828496.
  • Pintado Outumuro E, Morin Fraile V, Salvador González B, Benito L, Julve Ibáñez M, Sancho Campos MP et al. Exploring the factors influencing evidence-based approaches to advanced chronic kidney disease: a qualitative study involving nurses and physicians. BMC Prim Care. 2024; 25(1):177-177. PMID:38773496.
  • Zaldúa YC, Alòs F, Mur MC, Belmonte IA, Rodríguez VF, Vidal Alaball J. Analysis of the interruptions generated by the use of smartphones among Primary Care Health professionals. Aten Primaria. 2024; 56(4):102855-102855. PMID:38232681.
  • García Sancha N, Corchado Cobos R, Blanco Gómez A, Cunillera Puértolas O, Marzo Castillejo M, Castillo Lluva S et al. Cabergoline as a Novel Strategy for Post-Pregnancy Breast Cancer Prevention in Mice and Human. Res Sq. PMID:38405932.
Anar a l'inici